The 2016 European League Against Rheumatism recommends that treatment escalation is relevant if there is evidence of active arthritis regarding swollen joints and/or at least moderate disease activity, as evaluated by the joint condition (the number of swollen and tender joints) and an inflammatory reaction based on laboratory examinations of C-reactive protein (CRP) and erythrocyte sedimentation rate [5]. Here, CRP is linked to arthritic joint disease.